Mereo BioPharma (UK) Today
| 0A9G Stock | 2.87 0.07 2.38% |
Performance0 of 100
| Odds Of DistressOver 69
|
Mereo BioPharma is selling for under 2.87 as of the 31st of January 2025; that is 2.38% down since the beginning of the trading day. The stock's lowest day price was 2.85. Mereo BioPharma has more than 69 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 1st of January 2025 and ending today, the 31st of January 2025. Click here to learn more.
Business Domain Commercial & Professional Services | Classification Industrials |
Mereo BioPharma is entity of United Kingdom. It is traded as Stock on LSE exchange. More on Mereo BioPharma Group
Moving together with Mereo Stock
| 0.65 | SBID | State Bank Earnings Call Tomorrow | PairCorr |
Moving against Mereo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mereo Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Mereo BioPharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Mereo BioPharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO CoFounder | Denise ScotsKnight |
| Business Concentration | Environmental & Facilities Services, Commercial & Professional Services, Industrials, Industrials, Commercial Services & Supplies, Commercial & Professional Services, Industrials (View all Sectors) |
Mereo BioPharma Group (0A9G) is traded on London Exchange in UK and employs 33 people. Mereo BioPharma is listed under Environmental & Facilities Services category by Fama And French industry classification. The company operates under Commercial Services & Supplies sector and is part of Industrials industry.
Mereo BioPharma generates negative cash flow from operations
Check Mereo BioPharma Probability Of Bankruptcy
Ownership AllocationThe majority of Mereo BioPharma outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mereo BioPharma Group to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mereo BioPharma Group. Please pay attention to any change in the institutional holdings of Mereo BioPharma as this could imply that something significant has changed or is about to change at the company.
Check Mereo Ownership Details
Mereo BioPharma Group Risk Profiles
Although Mereo BioPharma's alpha and beta are two of the key measurements used to evaluate Mereo BioPharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.25 | |||
| Standard Deviation | 4.71 | |||
| Variance | 22.21 | |||
| Risk Adjusted Performance | (0.08) |
Mereo Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Mereo BioPharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Mereo BioPharma Corporate Management
Elected by the shareholders, the Mereo BioPharma's board of directors comprises two types of representatives: Mereo BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mereo. The board's role is to monitor Mereo BioPharma's management team and ensure that shareholders' interests are well served. Mereo BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mereo BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine CPA | Chief Officer | Profile | |
| Bo Kara | Senior CMC | Profile | |
| Fiona Bor | Head Property | Profile | |
| John Lewicki | Chief Officer | Profile | |
| Jackie Parkin | Therapy Endocrinology | Profile |
Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.